Connect
← Return to Prostate Biopsy Complication
Discussion
Prostate Cancer | Last Active: 4 days ago | Replies (32)
Comment receiving replies
The MPS2 test achieves 95-99% sensitivity and negative predictive value, making it highly reliable in ruling out significant cancers.
However, its specificity for detecting clinically significant prostate cancer (Grade Group ≥2) is approximately 80% at the rule-in threshold. This means about 20% of positive results could be false positives.
https://www.nature.com/articles/s41391-022-00633-3
Replies to "The MPS2 test achieves 95-99% sensitivity and negative predictive value, making it highly reliable in ruling..."
Connect
Here’s a nice summary of the MPS2 test.
https://prevention.cancer.gov/news-and-events/blog/improved-prostate-cancer-biomarker-test-may-help-men-avoid-unnecessary-biopsy
I note the following comment by Arul Chinnaiyan, M.D., Ph.D., S.P. Hicks Endowed Professor of Pathology and Urology and director of the Michigan Center for Translational Pathology at the University of Michigan:
“Approximately 75% of men who undergo biopsy do not have a cancer that needs to be treated. The MPS2 test provides additional information that can help avoid invasive biopsies and the discomfort and potential complications they bring.”
As I said before there’s an enormous need for something other than than the standard invasive biopsy.
Maybe this MPS2 test is the beginning of even better biopsy options that are “just over the horizon.”